CPhI Annual Reports - how accurate were they 5 years on?27 Jul 2017
The CPhI predictions foresaw advancement in QbD, continuous processing, and a dramatic rise in FDA warning letters.
CPhI Worldwide, organized by UBM, announces the 2017 expert panel for the highly anticipated CPhI Worldwide Annual Industry Report (5th edition), which will be released in two parts - part one in late summer and part two during CPhI Worldwide (24-26 October 2017 in Frankfurt). The report is a comprehensive and critically important publication that analyses key trends and innovations forecast by a panel of world-class experts.
Since this is the 5th edition, CPhI Worldwide has decided to look back at previous Annual Reports to see how accurate the predictions were. These included the expanded use of PAT, QbD, serialization, green chemistry and R&D improvements, as well as the rise of strategic relationships between pharma and CMOs (or CDMOs as they are now called). However, a potential hindrance to the industry was the predicted rise in the number of FDA warning letters.
The 2013 Annual Report forewarned of the rapid increase of FDA warning letters as a result of a tightening regulation environment and a lagging industry. This prediction proved entirely accurate with FDA warning letters tripling over the past few years, from 4882 in 2012 to 14,590 in 2016. Another bold prediction from the first report was an expected boom in pharmaceutical R&D and improvements in development cycles. Interestingly, this was true in 2014 and 2015, stellar years for New Molecular Entities (NMEs)) and Biologics License Applications (BLAs), with 41 and 45 FDA approvals, respectively. This increased productivity, however, dropped off significantly in the following years, with 22 in 2016 and a similar number anticipated for 2017.
As predicted, PAT, QbD and serialization have now become industry-wide practices that further ensure quality and efficiency. Another trend identified, is the implementation of continuous processing in both Big Pharma and CDMOs for APIs and finished products, and the use of these technologies is now increasing. In addition, both pharma and outsourcing providers were correctly anticipated by the reports to begin looking at green chemistry, route scouting and process improvements earlier in development to make less wasteful products and this has already begun taking shape across the industry.
CMOs were anticipated to grow in prominence across the industry, with strategic pharma partnerships proliferating. In the past 2 years, mega-mergers were expected to become more frequent amid the aggressive competition to become leading and full service providers. This is perhaps best highlighted by the recent deals struck between a number of CDMOs and pharma companies, as well as the purchase of Patheon by Thermo Fisher. In addition, Big Pharma has also set-up co-development deals with a number of companies, particularly to develop and commercialise biologics and biosimilars.
However, some of the first Annual Reports missed the pulse of the industry, expecting tighter regulations to have a consequential effect of decreasing the number of biotechs and small companies entering the market. In contrast, the biotech environment has significantly heated up in last couple of years, with the traditional hot spots in the US seeing growth as well as a rapid emergence of newer biotech hubs – particularly in China.
This year’s CPhI Annual Report features 12 experts that provide valuable insight on the current and future state of our industry, including manufacturing, R&D, regulations, biologics, PAT/QbD, and innovation, among many others.The CPhI Expert Panel members for 2017 are
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
'Tamper-evident' benefits are evident
28 Feb 2019
2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.Read more
Japan solid dose market predicted to bloom in 2019
21 Feb 2019
Executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and the second fastest overall country for biologicals growth.Read more
Pharma in South East Asia booming as CPhI opens event for the first time in Thailand
27 Feb 2019
Healthcare and pharmaceutical reforms, designed to increase access to high-value medicines, driving growth.Read more
Pharmapack Europe 2019 Award Winners
7 Feb 2019
Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.Read more
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
27 Jan 2019
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.Read more
Fiera Milano to host CPhI Worldwide 2020
20 Jan 2019
The exhibition district will see the world's largest pharma industry event.Read more
BASF’s new active ingredients target skin conditions’ root causes
15 Jan 2019
New active ingredients coming from the research of BASF’s innovation platforms on epigenetics, microbiome and extraction.Read more
Future-oriented packaging concepts from Sanner
11 Dec 2018
Company will showcase a range of packaging solutions, from desiccant and customized packaging to smart packaging solutions, at Pharmapack.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation